EDVA
Endovia Health Sciences, Inc.
There isn't enough reported data to score EDVA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
EDVA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
EDVA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EDVA PE Valuation
EDVA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EDVA Forward outlook
There aren't enough analyst estimates for EDVA to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EDVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$77.19 | -$1.47 |
| Q1 2024 | -$80.39 | -$0.74 |
| Q4 2023 | -$78.40 | +$12.84 |
| Q3 2021 | -$174.99 | -$154.19 |
| Q2 2021 | -$121.58 | -$107.18 |
| Q1 2021 | -$84.81 | -$70.41 |
| Q4 2020 | -$83.20 | -$76.80 |
| Q3 2020 | -$20.80 | -$19.00 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 202% for EDVA versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
EDVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $4.2K | -99% |
| Q1 2025 | $438.3K | -72% |
| Q4 2024 | $585.9K | -78% |
| Q3 2024 | $981.9K | -81% |
| Q2 2024 | $1M | -80% |
| Q1 2024 | $1.5M | -74% |
| Q4 2023 | $2.7M | -44% |
| Q3 2023 | $5.1M | +5.6% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for EDVA versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -23176% | -22078 points |
| Q1 2025 | -464% | -253 points |
| Q4 2024 | -1098% | -976 points |
| Q3 2024 | -272% | -188 points |
| Q2 2024 | -353% | -271 points |
| Q1 2024 | -211% | -152 points |
| Q4 2023 | -122% | -23 points |
| Q3 2023 | -84% | +21 points |
EDVA's operating margin was −23176% last quarter, down 22824 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
EDVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.1M | -$411.4K |
| Q1 2026 | -$930.5K | -$206.4K |
| Q2 2025 | -$680.3K | +$1.7M |
| Q1 2025 | -$724.1K | +$583.8K |
| Q3 2024 | -$2.6M | -$663.7K |
| Q2 2024 | -$2.4M | -$9.8K |
| Q1 2024 | -$1.3M | +$2.8M |
| Q4 2023 | -$1.7M | +$1.8M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with EDVA at up 71%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
EDVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.6% | +27K shares |
| 1 year | +17% | +44.1K shares |
| 3 years | +80% | +136K shares |
EDVA has 306,974 diluted shares, up 17% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EDVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EDVA Net Leverage
EDVA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EDVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 7.9 | Oversold |
EDVA's weekly RSI is 31 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EDVA PE vs Healthcare Sector
EDVA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EDVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 5.9% below |
| 20 week MA | $0.30 | 47% below |
| 50 week MA | $1.40 | 89% below |
| 100 week MA | $8.44 | 98% below |
| 200 week MA | $55.4 | 100% below |
EDVA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EDVA on trend strength, trading above more of its moving averages.
EDVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $524.8 | $190.4 | -64% |
| 2022 | $190.4 | $135.2 | -29% |
| 2023 | $135.2 | $88.4 | -35% |
| 2024 | $88.4 | $28.0 | -68% |
| 2025 | $28.0 | $3.85 | -86% |
| 2026 YTD | $3.85 | $0.16 | -96% |
EDVA has finished every year since 2021 lower, and it's down 96% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EDVA on returns for 2026, with the stronger performance.